A PET study in healthy subjects of brain exposure of 11C-labelled osimertinib – A drug intended for treatment of brain metastases in non-small cell lung cancer

Andrea Varrone,Katarina Varnäs,Aurelija Jučaitė,Zsolt Cselényi,Peter Johnström,Magnus Schou,Ana Vazquez-Romero,Mohammad Mahdi Moein,Christer Halldin,Andrew P. Brown,Karthick Vishwanathan,Lars Farde

A PET study in healthy subjects of brain exposure of 11C-labelled osimertinib – A drug intended for treatment of brain metastases in non-small cell lung cancer

2019

Andrea Varrone
Katarina Varnäs
Aurelija Jučaitė
Zsolt Cselényi
Peter Johnström
Magnus Schou
Ana Vazquez-Romero
Mohammad Mahdi Moein
Christer Halldin
Andrew P. Brown
Karthick Vishwanathan
Lars Farde

Osimertinib is a tyrosine kinase inhibitor (TKI) of the mutated epidermal growth factor receptor (EGFRm) with observed efficacy in patients with brain metastases. Brain exposure and drug distributi...

Keywords:

Oncology
Osimertinib
Anesthesia
Drug
Cell
Diabetes mellitus
Lung cancer
Biology
Internal medicine
Blood–brain barrier
Cancer research
Tyrosine-kinase inhibitor
Epidermal growth factor receptor
Brain metastasis

Correction
Source
Cite
Save
Machine Reading By IdeaReader

References

Citations